IT Brief US - Technology news for CIOs & IT decision-makers
United States
Remedy Robotics raises USD $62 million for stroke trials

Remedy Robotics raises USD $62 million for stroke trials

Mon, 16th Nov 2026 (Today)
Karen Joy Bacudo
KAREN JOY BACUDO Finance Editor

Remedy Robotics has raised USD $62 million in a Series B funding round.

The round was led by DCVC, with backing from Australian investors Blackbird, HESTA and Hostplus.

The San Francisco-based medical robotics company will use the funding to advance clinical trials and regulatory work for its N1 System, a robotic platform for cardiovascular and endovascular procedures. It is preparing a pivotal clinical trial in partnership with the University of California and working towards US Food and Drug Administration approval for neurovascular intervention.

Other investors included UC Investments, Skip Capital, Build Collective, Divergent Capital and KdT Ventures. Several existing investors also increased their support in the latest financing.

Remedy was co-founded by Australian-trained former cardiac surgeon Dr David Bell. The company develops robotic systems designed to let specialist doctors carry out procedures either on site or remotely, with a focus on time-critical conditions including stroke and other cardiovascular emergencies.

It has already demonstrated fully robotic and fully remote neurointerventional procedures. Remedy is now working with more than 100 hospitals worldwide and plans to place prototype systems across its clinical partner network.

Clinical push

Access to endovascular intervention remains limited because only a small number of hospitals have the specialist staff needed to perform these procedures, Remedy said. The company argues that remote robotic treatment could widen access in regional and underserved areas where patients are far from specialist centres.

In Australia, Remedy is partnering with the Australian Stroke Alliance to explore trials. The concept would allow a stroke specialist in one city to treat a patient in a distant regional hospital without travelling to the site.

"Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that's devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common," said Dr David Bell, Chief Executive Officer and Co-founder of Remedy Robotics.

"This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography," Bell said.

The N1 System is still under development and is not approved for clinical use or sale. Remedy said the platform uses machine learning to analyse preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration, and carry out endovascular procedures robotically.

Investor backing

The funding adds to growing investor interest in medical robotics and AI-driven tools for specialist care. For Remedy, support from US and Australian institutional investors gives the company backing as it moves from development into formal clinical testing.

DCVC said Remedy was addressing a practical access problem in healthcare rather than developing technology in isolation.

"Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges," said James Hardiman, General Partner at DCVC.

"We believe the company is uniquely positioned to redefine how life-saving intervention is delivered and are thrilled to support them as they advance toward broader clinical and commercial adoption," Hardiman said.

Jake Sganga, Remedy's Chief Technology Officer and Co-founder, said the next phase of work would centre on trials, regulatory progress and greater automation within the system.

"This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 System toward clinical trials and potential FDA approval, while also developing additional features including full autonomy," Sganga said.

"We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, as we prepare for our planned pivotal clinical trials across the UC network," he said.

Blackbird said it viewed Remedy as tackling a large unmet need in global healthcare.

"Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category," said Michael Tolo, Partner at Blackbird.

"We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth," Tolo said.